AG
PTCT icon

Aperio Group’s PTC Therapeutics PTCT Stock Holding History

Aperio Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$918K Buy
15,046
+2,203
+17% +$130K ﹤0.01% 1639
2020
Q3 		$600K Buy
12,843
+2,855
+29% +$141K ﹤0.01% 1717
2020
Q2 		$507K Buy
9,988
+3,469
+53% +$170K ﹤0.01% 1771
2020
Q1 		$291K Buy
6,519
+1,537
+31% +$77.4K ﹤0.01% 1920
2019
Q4 		$239K Buy
+4,982
New +$212K ﹤0.01% 2142
2019
Q3 		– Sell
-3,738
Closed -$168K – 2649
2019
Q2 		$168K Buy
+3,738
New +$148K ﹤0.01% 2236

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's PTCT Position: Q4 2020 in Review

Aperio Group increased its PTC Therapeutics (PTCT) stake by 17% in Q4 2020, buying an estimated $130K and bringing the position to 15,046 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Aperio Group first reported a position in PTCT in Q2 2019 and has held it in 6 quarters since. 215 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

  • Aperio Group held 15,046 shares of PTC Therapeutics worth $918K as of Q4 2020.
  • Aperio Group bought 2,203 PTC Therapeutics shares in Q4 2020, an estimated $130K.
  • PTC Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1639 holding.
  • Aperio Group first reported a position in PTC Therapeutics in Q2 2019 and has held it in 6 quarters since.
  • 215 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.